ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

9478	Companies
185484	Keywords
117839	Articles
99329	Press releases

Home
Companies
ABIVAX

BRIEF

published on 10/03/2024 at 08:35, 1 year 2 months ago

Abivax Announces Positive Results for Obefazimod in Ulcerative Colitis Treatment

Abivax Obefazimod Ulcerative Colitis Clinical Study Safety Analysis
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 year 2 months ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax announces positive interim results of obefazimod in ulcerative colitis patients after 2 years, showing maintenance of remission and safety profile consistency

Abivax Obefazimod Ulcerative Colitis Safety Efficacy
BRIEF

published on 09/26/2024 at 08:35, 1 year 2 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Obefazimod Ulcerative Colitis Phase 2b Study UEG Week 2024
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 2 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to present Phase 2b trial results of obefazimod in ulcerative colitis at UEG Week 2024, showcasing efficacy and safety data for potential oral therapy

Abivax Obefazimod Ulcerative Colitis Clinical Trial UEG Week 2024
BRIEF

published on 09/25/2024 at 22:06, 1 year 2 months ago

Abivax Announces Ulcerative Colitis Combination Therapy Strategy and Preclinical Data

Obefazimod Ulcerative Colitis Preclinical Data Combination Therapy Etrasimod
PRESS RELEASE

published on 09/25/2024 at 22:01, 1 year 2 months ago

Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
Abivax announces preclinical data of Obefazimod and Etrasimod combination therapy in IBD mouse model, aiming to break through efficacy ceiling in UC treatment. More updates expected in Q4 2024

Abivax Obefazimod Preclinical Data Etrasimod IBD Mouse Model
BRIEF

published on 09/19/2024 at 18:05, 1 year 2 months ago

ABIVAX: Number of shares and voting rights as of August 31, 2024

Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF

published on 09/09/2024 at 23:01, 1 year 2 months ago

Statement by Marc de Garidel on Abivax's 2024 Half-Year Financial Report

Financial Report Abivax Transparency IFRS Heritage
BRIEF

published on 09/09/2024 at 22:40, 1 year 2 months ago

ABIVAX presents its 2024 half-year results

Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF

published on 09/09/2024 at 22:06, 1 year 2 months ago

Abivax financial results for the first half of 2024

Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms

Accesswire

Published on 12/05/2025 at 15:35, 15 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 25 minutes ago

Usha Resources Provides Corporate Updates
Published on 12/05/2025 at 15:00, 50 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 50 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 50 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 15:47, 2 minutes ago

Form 8.3 - The Vanguard Group, Inc.: NCC Group plc
Published on 12/05/2025 at 15:39, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc
Published on 12/05/2025 at 15:38, 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/05/2025 at 15:36, 13 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Published on 12/05/2025 at 15:35, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.

Les Echos

Published on 12/05/2025 at 15:10, 39 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 7 hours 5 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 21 hours 50 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 22 hours 5 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 22 hours 6 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution

View all LES ECHOS COMFI WIRE